Toronto, Ontario–(Newsfile Corp. – July 19, 2022) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, announced today that it’s proprietary Amanita Muscaria Extract (AME-1) is now available for preorder in the USA. The company offers consumers a unique opportunity to purchase a safe and legal extract of the mushroom that has been used for thousands of years by various groups around the world for its healing properties.
Psyched has approval to sell in the United States via Self-GRAS (Generally Regarded as Safe) designation, which allows the company to sell its AME-1 products. The company plans to submit the application for AME-1 as an NDI (a New Dietary Ingredient) to the FDA this fall. The product, called Calm, facilitates rest within the body and mind, and does not require a prescription. This leaves the retail landscape open to many possibilities for distribution and listing potential.
Chief Commercial Officer, Matthew Singh, commented: “Our entire team is excited to take this step into full-scale commercialization. We begin with the launch of Calm, then follow with additional skus and product innovation. Our presale initiative will build a sales pipeline and [hopefully] attract the attention of all individuals with an interest in this sector. We firmly believe our product offerings will separate us from the pack when compared to any other mushroom company on the market today. Try Calm, the very first legal Amanita Muscaria product for sale in the United States, and discover what separates Psyched Wellness from all other companies working within our discipline.”
To preorder Calm, visit shop.psyched-wellness.com.
Psyched Wellness has not been evaluated by the United States Food and Drug Administration or any other similar body of another jurisdiction. Psyched Wellness products are not a substitute for professional medical care.
For further information, please contact:
Chief Executive Officer
Psyched Wellness Ltd.
Email: [email protected]
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the Company’s ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/131266